Home » Stocks » CPIX

Cumberland Pharmaceuticals, Inc. (CPIX)

Stock Price: $2.66 USD 0.06 (2.37%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 39.69M
Revenue (ttm) 37.44M
Net Income (ttm) -3.34M
Shares Out 14.92M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.66
Previous Close $2.60
Change ($) 0.06
Change (%) 2.37%
Day's Open 2.80
Day's Range 2.66 - 2.85
Day's Volume 60,917
52-Week Range 2.58 - 3.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 600.00% over the past year to $0.07, which b...

1 day ago - Benzinga

NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial re...

1 day ago - PRNewsWire

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's look at Cumberland's Q1 earnings report.

2 days ago - Benzinga

NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2021 financial results and Company update after the market...

1 week ago - PRNewsWire

Seattle-based Tegria, a healthcare services and tech company that Providence launched last year, announced the acquisition of Franklin, Tenn.

1 month ago - GeekWire

Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 88.89% over the past year to $0.01, which beat th...

2 months ago - Benzinga

NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, toda...

2 months ago - PRNewsWire

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's look at Cumberland's Q4 earnings report.

2 months ago - Benzinga

NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update af...

2 months ago - PRNewsWire

NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection....

5 months ago - PRNewsWire

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Cumberland (CPIX) delivered earnings and revenue surprises of 128.57% and 7.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of Cumberland (NASDAQ:CPIX) were flat after the company reported Q3 results. Quarterly Results Earnings per share increased 100.00% over the past year to $0.02, which beat the estimate of ($0.07).

6 months ago - Benzinga

NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial r...

6 months ago - PRNewsWire

Cumberland (NASDAQ: CPIX) unveils its next round of earnings this Tuesday, November 10. Get prepared with Benzinga's ultimate preview for Cumberland's Q3 earnings.

6 months ago - Benzinga

NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the marke...

6 months ago - PRNewsWire

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

ATLANTA, Sept. 28, 2020 /PRNewswire/ -- Women's apparel and fashion accessories retailer, Charming Charlie, today announced that it will open its first physical store at the Cumberland Mall in Atlanta, ...

7 months ago - PRNewsWire

SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #Calix--Cumberland Connect is deploying FTTH with Calix and has completed an end-to-end network integration 83 percent faster than industry standards

8 months ago - Business Wire

NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

8 months ago - PRNewsWire

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A.

9 months ago - Seeking Alpha

Cumberland (CPIX) delivered earnings and revenue surprises of 166.67% and 3.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of Cumberland (NASDAQ:CPIX) rose 2.07% in after-market trading after the company reported Q2 results.

9 months ago - Benzinga

NASHVILLE, Tenn., Aug. 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

9 months ago - PRNewsWire

Cumberland (NASDAQ: CPIX) releases its next round of earnings this Tuesday, August 11.

9 months ago - Benzinga

NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

9 months ago - PRNewsWire

NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.

9 months ago - PRNewsWire

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detai...

11 months ago - PRNewsWire

Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a com...

11 months ago - PRNewsWire

Here are four top-ranked liquid gems that investors can add to portfolio for remarkable returns.

Other stocks mentioned: EXPI, MED, NPTN
11 months ago - Zacks Investment Research

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: AMAG, MIST
1 year ago - Zacks Investment Research

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: ALIM, OSG, RRTS, TTNP
1 year ago - Investopedia

Cumberland Pharmaceuticals Inc (CPIX) CEO A. J. Kazimi on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Cumberland (CPIX) delivered earnings and revenue surprises of 800.00% and 20.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Cumberland (CPIX) delivered earnings and revenue surprises of -90.91% and -18.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals (CPIX) closed at $5.56 in the latest trading session, marking a -0.18% move from the prior day.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

1 year ago - Zacks Investment Research

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals (CPIX) closed at $5.34 in the latest trading session, marking a +0.75% move from the prior day.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals (CPIX) closed at $5.30 in the latest trading session, marking a -1.6% move from the prior day.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

1 year ago - Zacks Investment Research

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET

1 year ago - Seeking Alpha

About CPIX

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylo... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Aug 11, 2009
Stock Exchange
NASDAQ
Ticker Symbol
CPIX
Full Company Profile

Financial Performance

In 2020, CPIX's revenue was $37.44 million, an increase of 8.88% compared to the previous year's $34.39 million. Losses were -$3.34 million, -5.61% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CPIX stock is "Strong Buy" and the 12-month stock price forecast is 8.50.

Price Target
$8.50
Analyst Consensus: Strong Buy